Molecular Pathology of Bone and Soft Tissue Tumors

Cell and Tissue Based Molecular Pathology

Volumn , Issue , 2009, Pages 325-359

  Rubin, Brian P ^a   Lazar, Alexander J F ^b   Oliveira, Andre M ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c Genitourinary Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74549131901     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044306901-7.50031-6     Document Type: Chapter

References (187)

1. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
2. Naka N, Tomita Y, Nakanishi H, et al. Mutations of p53 tumor suppressor gene in angiosarcoma. Int J Cancer 1997, 71:952-955.
3. Przygodzki RM, Finkelstein SD, Keohavong P, et al. Sporadic and thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in KRAS-2. Lab Invest 1997, 76:153-159.
4. Zietz C, Rossie M, Haas C, et al. MDM2 oncoprotein overexpression, p53 gene mutation, and VEGF upregulation in angiosarcomas. Am J Pathol 1998, 153:1425-1433.
5. Bovee JVMG, Cleton-Jansen AM, Taminiau HM, Hogendoorn CW Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6:599-607.
6. Mandahl N, Gustafson P, Mertens F, et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer 2002, 33:188-200.
7. Sandberg AA Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004, 16:342-354.
8. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and choroids tumours: A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002, 196:194-203.
9. Chadwick EG, Connor EJ, Hanson IC, et al. Tumors of smooth-muscle origin in HIV-infected children. JAMA 1990, 263:3182-3184.
10. Dei Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996, 148:1037-1045.
11. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
12. Sandberg AA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Leiomyosarcoma. Cancer Genet Cytogenet 2005, 161:1-19.
13. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System 2000, IARC Press, Lyon. P. Kleihues, W.K. Cavenee (Eds.).
14. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group. J Pathol 2000, 190:31-38.
15. Mertens F, Rydhom A, Bauer HF, et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 1995, 61:793-798.
16. Boehm AK, Neff JR, Squire JA, et al. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Ped Pathol Mol Med 2000, 19:359-376.
17. Bridge JA, Nelson M, McComb E Cytogenetic findings in 73 osteosarcoma specimens and a review of the literatures. Cancer Genet Cytogenet 1997, 95:74-87.
18. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004, 39:11-21.
19. Wang LL Biology of osteogenic sarcoma. Cancer J 2005, 11:294-305.
20. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
21. Mertens F, Fletcher CDM, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: A report of the CHAMP study group. Genes Chromosomes Cancer 1998, 22:16-25.
22. Argani P, Ladanyi M Translocation carcinomas of the kidney. Clin Lab Med 2005, 25:363-378.
23. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: A sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003, 27:750-761.
24. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL/TFE3 gene fusion of alveolar soft part sarcoma: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001, 159:179-192.
25. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001, 20:48-57.
26. Ladanyi M, Antonescu CR, Drobnjak M, et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 2002, 160:1215-1221.
27. Lazar AJ, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007, 15(24):7314-7321. 13.
28. Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma: A clinicopathologic study of half a century. Cancer 1989, 63:1-13.
29. Ordonez N, Ladanyi M, et al. Alveolar soft part sarcoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 208-210. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
30. Dal Cin P, Kozakewich HP, Goumnerova L, et al. Variant translocations involving 16q22 and 17p13 in solid variant and extraosseous forms of aneurysmal bone cyst. Genes Chromosomes Cancer 2000, 28:233-234.
31. Jaffe H, Lichtenstein L Solitary unicameral bone cyst, with emphasis on the roentgen picture, the pathologic appearance and the pathogenesis. Arch Surg 1942, 44:1004-1025.
32. Martinu L, Masuda-Robens JM, Robertson SE, et al. The TBC (Tre-2/Bub2/Cdc16) domain protein TRE17 regulates plasma membrane-endosomal trafficking through activation of Arf6. Mol Cell Biol 2004, 24:9752-9762.
33. Masuda-Robens JM, Kutney SN, Qi H, Chou MM The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling. Mol Cell Biol 2003, 23:2151-2161.
34. Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005, 24:3419-3426.
35. Oliveira AM, Hsi BL, Weremowicz S, Rosenberg AE, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004, 64:1920-1923.
36. Oliveira AM, Perez-Atayde AR, Inwards CY, Medeiros F, et al. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 2004, 165:1773-1780.
37. Panoutsakopoulos G, Pandis N, Kyriazoglou I, Gustafson P, et al. Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer 1999, 26:265-266.
38. Rosenberg A, Nielsen G, Fletcher J Aneurysmal bone cyst. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 338-339. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
39. Antonescu CR, Dal Cin P, Nafa K, Teot LA, et al. EWS/CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer 2007, 46:1051-1060.
40. Antonescu CR, Nafa K, Segal NH, et al. EWS/CREB1: A recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 2006, 12:5356-5362.
41. Costa MJ, Weiss SW Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol 1990, 14:1126-1132.
42. Enzinger FM Angiomatoid malignant fibrous histiocytoma: A distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer 1979, 44:2147-2157.
43. Hallor KH, Micci F, Meis-Kindblom JM, et al. Fusion genes in angiomatoid fibrous histiocytoma. Cancer Lett 2006, 25:158-163.
44. Hallor KH, Mertens F, Jin Y, et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer 2005, 44:97-102.
45. Waters BL, Panagopoulos I, Allen EF Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet Cytogenet 2000, 121:109-116.
46. Antonescu CR, Nafa K, Segal NH, et al. EWS/CREB1: A recurrent variant fusion in clear cell sarcoma: Association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 2006, 12:5356-5362.
47. Chung EB, Enzinger FM Malignant melanoma of soft parts: A reassessment of clear cell sarcoma. Am J Surg Pathol 1983, 7:405-413.
48. Coindre JM, Hostein I, Terrier P, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: Clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer 2006, 107:1055-1064.
49. Davis IJ, Kim JJ, Ozsolak F, et al. Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiTF family of human cancers. Cancer Cell 2006, 9:473-484.
50. Kawai A, Hosono A, Nakayama R, et al. Clear cell sarcoma of tendons and aponeuroses: A study of 75 patients. Cancer 2007, 109:109-116.
51. Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer 2002, 99:560-567.
52. Patel RM, Downs-Kelly E, Weiss SW, et al. Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol 2005, 18:1585-1590.
53. Sandberg AA, Bridge JA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Clear cell sarcoma (malignant melanoma of soft parts). Cancer Genet Cytogenet 2001, 130:1-7.
54. Sciot R, Speleman F Clear cell sarcoma of soft tissue. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 211-212. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
55. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993, 4:341-345.
56. Granter SR, Renshaw AA, Kozakewich HP, Fletcher JA The pericentromeric inversion, inv (6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma. Mod Pathol 1998, 11:1071-1074.
57. Safar A, Nelson M, Neff JR, et al. Recurrent anomalies of 6q25 in chondromyxoid fibroma. Hum Pathol 2000, 31:306-311.
58. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the chromosomes and morphology (CHAMP) collaborative study group. J Pathol 2002, 196:194-203.
59. Ostrowski JM, Spjut HJ, Bridge JA Chondromyxoid Fibroma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 243-245. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
60. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear β-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 2005, 29:653-659.
61. Latchford A, Volikos E, Johnson V, et al. APC mutations in FAP-associated desmoid tumours are nonrandom but not "just right.". Hum Mol Genet 2007, 16:78-82.
62. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007, 25:1785-1791.
63. Tejpar S, Nollet F, Li C, et al. Predominance of β-catenin mutations and β-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999, 18:6615-6620.
64. Antonescu CR, Gerald WL, Magid MS, Ladanyi M Molecular variants of the EWS/WT1 gene fusion in desmoplastic small round cell tumor. Diagn Mol Pathol 1998, 7:24-28.
65. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
66. Sandberg AA, Bridge JA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. desmoplastic small round-cell tumors. Cancer Genet Cytogenet 2002, 138:1-10.
67. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001, 98:6348-6353.
68. Micci F, Panagopoulos I, Bjerkehagen B, Heim S Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 2006, 66:107-112.
69. Boudousquie AC, Lawce HJ, Sherman R, et al. Complex translocation (7;22) identified in an epithelioid hemangioendothelioma. Cancer Genet Cytogenet 1996, 92:116-121.
70. He M, Das K, Blacksin M, et al. A translocation involving the placental growth factor gene is identified in an epithelioid hemangioendothelioma. Cancer Genet Cytogenet 2006, 168:150-154.
71. Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 2001, 25:684-687.
72. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004, 100:1053-1058.
73. Bridge RS, Rajaram V, Dehner LP, et al. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: A comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 2006, 19:1-8.
74. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
75. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: A study of 66 genetically confirmed cases. Am J Surg Pathol 2005, 29:1025-1033.
76. Khoury JD Ewing sarcoma family of tumors. Adv Anat Pathol 2005, 12:212-220.
77. Sandberg AA, Bridge JA Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet 2000, 123:1-26.
78. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
79. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma: Cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 2003, 162:781-792.
80. Cohen MM The new bone biology: Pathologic, molecular and clinical correlates. Am J Med Genet A 2006, 40:2646-2706.
81. de Sanctis L, Delmastro L, Russo MC, et al. Genetics of McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006, 19(Suppl 2):577-582.
82. Idowu BD, Al-Adnani M, O'Donnell P, et al. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: The first report of a codon 227 mutation in bone. Histopathology 2007, 50:691-704.
83. Rubin BP, Duensing A Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 2006, 86:981-986.
84. Rubin BP, Heinrich MC, Corless CL Gastrointestinal stromal tumour. Lancet 2007, 369:1731-1741.
85. Rubin BP Gastrointestinal stromal tumors: An update. Histopathology 2006, 48:83-96.
86. Gisselsson D, Hoglund M, Mertens F, et al. Hibernomas are characterized by homozygous deletions in the multiple endocrine neoplasia type I region. Metaphase fluorescence in situ hybridization reveals complex rearrangements not detected by conventional cytogenetics. Am J Pathol 1999, 155:61-66.
87. Maire G, Forus A, Foa C, et al. 11q13 alterations in two cases of hibernoma: Large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5. Genes Chromosomes Cancer 2003, 37:389-395.
88. Mrozek K, Karakousis CP, Bloomfield CD Band 11q13 is nonrandomly rearranged in hibernomas. Genes Chromosomes Cancer 1994, 9:145-147.
89. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH Molecular detection of the ETV6/NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000, 24:937-946.
90. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
91. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6/NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998, 18:184-187.
92. Lannon CL, Sorensen PH ETV6/NTRK3: A chimeric protein kinase with transformation activity in multiple cell lineages. Semin Cancer Biol 2005, 15:215-223.
93. Coffin CM, Hornick JL, Fletcher CD Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007, 31:509-520.
94. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3/ALK and TPM4/ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157:377-384.
95. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003, 37:98-105.
96. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003, 12:1241-1252.
97. Hornick JL, Fletcher CD Criteria for malignancy in nonvisceral smooth muscle tumors. Ann Diagn Pathol 2003, 7:60-66.
98. Nucci MR, Drapkin R, Cin PD, et al. Distinctive cytogenetic profile in benign metastasizing leiomyoma: Pathogenetic implications. Am J Surg Pathol 2007, 31:737-743.
99. Quade BJ, Weremowicz S, Neskey DM, et al. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 2003, 63:1351-1358.
100. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-410.
101. Gisselsson D, Hibbard MK, Dal Cin P, et al. PLAG1 alterations in lipoblastoma: Involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am J Pathol 2001, 159:955-962.
102. Hibbard MK, Kozakewich HP, Dal Cin P, et al. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 2000, 60:4869-4872.
103. Kas K, Voz ML, Röijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and β-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 1997, 15:170-174.
104. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3/ALK and TPM4/ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000, 157:377-384.
105. Sciot R, Mandahl N Lipoblastoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 26-27. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
106. Bartuma H, Hallor KH, Panagopoulos I, et al. Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. Genes Chromosomes Cancer 2007, 46(6):594-606.
107. Dal CP, Sciot R, Polito P, et al. Lesions of 13q may occur independently of deletion of 16q in spindle cell/pleomorphic lipomas. Histopathology 1997, 31:222-225.
108. Fedele M, Battista S, Manfioletti G, et al. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 2001, 22:1583-1591.
109. Mayr C, Hemann MT, Bartel DP Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation. Science 2007, 315:1576-1579.
110. Mietinnen MM, Mandahl N Spindle cell lipoma/pleomorphiclipoma. WorldHealth Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 31-32. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
111. Nielsen GP, Mandahl N Lipoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 20-22. IARC Press, Lyon, 31-32. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
112. Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999, 24:30-41.
113. Petit MM, Mols R, Schoenmakers EF, et al. V LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 1996, 36:118-129.
114. Sandberg AA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Lipoma. Cancer Genet Cytogenet 2004, 150:93-115.
115. Willen H, Akerman M, Dal Cin P, et al. Comparison of chromosomal patterns with clinical features in 165 lipomas: A report of the CHAMP study group. Cancer Genet Cytogenet 1998, 102:46-49.
116. Matsuyama A, Hisaoka M, Shimajiri S, et al. Molecular detection of FUS/CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Am J Surg Pathol 2006, 30(9):1077-1084.
117. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 2005, 85(3):408-415.
118. Panagopoulos I, Moller E, Dahlen A, et al. Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera. Genes Chromosomes Cancer 2007, 46(2):181-191.
119. Panagopoulos I, Storlazzi CT, Fletcher CD, et al. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer 2004, 40(3):218-228.
120. Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet 2003, 12(18):2349-2358.
121. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of p53 status, TLS/CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: A molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001, 7:3977-3987.
122. Crozat A, Aman P, Mandahl N, Ron D Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644.
123. Engstrom K, Willén H, Kåbjörn-Gustafsson C, et al. The myxoid/round cell liposarcoma fusion oncogene FUS/DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006, 168:1642-1653.
124. Kilpatrick SE, Doyon J, Choong PF, et al. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996, 77:1450-1458.
125. Panagopoulos I, Höglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996, 12:489-494.
126. Panagopoulos I, Mertens F, Isaksson M, Mandahl N A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun 2000, 279:838-845.
127. Rabbitts TH, Forster A, Larson R, Nathan P Fusion of the dominant-negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993, 4:175-180.
128. Riggi N, Cironi L, Provero P, et al. Expression of the FUS/CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006, 66:7016-7023.
129. Boikos SA, Stratakis CA Carney complex: The first 20 years. Curr Opin Oncol 2007, 19:24-29.
130. Faivre L, Nivelon-Chevallier A, Kottler ML, et al. Mazabraud syndrome in two patients: Clinical overlap with McCune-Albright syndrome. Am J Med Genet 2001, 99:132-136.
131. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
132. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type Iα regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89-92.
133. Stratakis CA, Kirschner LS, Carney JA Clinical and molecular features of the Carney complex: Diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86:4041-4046.
134. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System 2000, IARC Press, Lyon. P. Kleihues, W.K. Cavenee (Eds.).
135. Maertens O, Brems H, Vandesompele J, et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 2006, 27:1030-1040.
136. Bridge JA, Nelson M, Orndal C, et al. Clonal karyotypic abnormalities of the hereditary multiple exostoses chromosomal loci 8q24.1 (EXT1) and 11p11-12 (EXT2) in patients with sporadic and hereditary osteochondromas. Cancer 1998, 82:1657-1663.
137. Duncan G, McCormick C, Tufaro F The link between heparan sulfate and hereditary bone disease: Finding a function for the EXT family of putative tumor suppressor proteins. J Clin Invest 2001, 108:511-516.
138. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and choroids tumours: A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002, 196:194-203.
139. Tiet TD, Alman BA Developmental pathways in musculoskeletal neoplasia: Involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway. Pediatr Res 2003, 53:539-543.
140. Unni K, Inwards C, Bridge J, et al. Tumors of the bones and joints 2005, Armed Forces Institute of Pathology, Washington, DC.
141. Wuyts W, Van HW Molecular basis of multiple exostoses: Mutations in the EXT1 and EXT2 genes. Hum Mutat 2000, 15:220-227.
142. Zak BM, Crawford BE, Esko JD Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta 2002, 19:346-355. 1573.
143. Dahlen A, Fletcher CD, Mertens F, et al. Activation of the GLI oncogene through fusion with the β-actin gene (ACTB) in a group of distinctive pericytic neoplasms: Pericytoma with t(7;12). Am J Pathol 2004, 164:1645-1653.
144. Dahlen A, Mertens F, Mandahl N, Panagopoulos I Molecular genetic characterization of the genomic ACTB/GLI fusion in pericytoma with t(7;12). Biochem Biophys Res Commun 2004, 325:1318-1323.
145. Barr FG, Qualman SJ, Macris MH, et al. Genetic herterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 2002, 62:4704-4710.
146. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
147. Fritsch MK, Bridge JA, Schuster AE, et al. Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatr Dev Pathol 2003, 6:43-53.
148. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest 2006, 86:547-556.
149. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3/FKHR and PAX7/FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002, 20:2672-2679.
150. Baser ME Contributors to the international NF2 mutation database. Hum Mutat 2006, 27:297-306.
151. Brooks DG The neurofibromatosis: Hereditary predisposition to multiple peripheral nerve tumors. Neurosurg Clin N Am 2004, 15:145-155.
152. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System 2000, IARC Press, Lyon. P. Kleihues, W.K. Cavenee (Eds.).
153. Endo M, Hasegawa T, Tashiro T, et al. Bizarre parosteal osteochondromatous proliferation with a t(1;17) translocation. Virchows Arch 2005, 447:99-102.
154. Nilsson M, Domanski HA, Mertens F, Mandahl N Molecular cytogenetic characterization of recurrent translocation breakpoints in bizarre parosteal osteochondromatous proliferation (Nora's lesion). Hum Pathol 2004, 35:1063-1069.
155. Storlazzi CT, Wozniak A, Panagopoulos I, et al. Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: Molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). Int J Cancer 2006, 118:1972-1976.
156. Zambrano E, Nosé V, Perez-Atayde AR, et al. Distinct chromosomal rearrangements in subungual (Dupuytren) exostosis and bizarre parosteal osteochondromatous proliferation (Nora lesion). Am J Surg Pathol 2004, 28:1033-1039.
157. Buddingh EP, Krallman P, Neff JR, et al. Chromosome 6 abnormalities are recurrent in synovial chondromatosis. Cancer Genet Cytogenet 2003, 140:18-22.
158. Sandberg AA Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004, 16:342-354.
159. Unni K, Inwards C, Bridge J, et al. Tumors of the bones and joints 2005, Armed Forces Institute of Pathology, Washington, DC.
160. Amary MF, Berisha F, Bernardi Fdel C, et al. Detection of SS18/SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: Analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod Pathol 2007, 20:482-496.
161. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994, 7:502-508.
162. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT/SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol 2004, 22:4040-4050.
163. Haldar M, Hancock JD, Coffin CM, et al. A conditional mouse model of synovial sarcoma: Insights into a myogenic origin. Cancer Cell 2007, 11:375-388.
164. Jin L, Majerus J, Oliveira A, et al. Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR. Diagn Mol Pathol 2003, 12:224-230.
165. Kawai A, Woodruff J, Healey JH, et al. SYT/SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998, 338:153-160.
166. Ladanyi M Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001, 20:5755-5762.
167. Lim FL, Soulez M, Koczan D, et al. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 1998, 17:2013-2018.
168. Oliveira AM, Fletcher CD Molecular prognostication for soft tissue sarcomas: Are we ready yet?. J Clin Oncol 2004, 22:4031-4034.
169. Sandberg AA, Bridge JA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Synovial sarcoma. Cancer Genet Cytogenet 2002, 133:1-23.
170. Weiss SW, Goldblum JR Enzinger and Weiss Soft Tissue Tumors 2001, Mosby, St Louis.
171. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
172. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006, 103:690-695.
173. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005, 29:1340-1347.
174. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994, 54:794-799.
175. Dei Tos A, Pedeutour F Dedifferentiated lipsarcoma. WorldHealth Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 38-39. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
176. Dei Tos A, Pedeutour F Atypical lipomatous tumour/well differentiated liposarcoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, 35-37. IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
177. Hostein I, Pelmus M, Aurias A, et al. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: A potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol 2004, 202:95-102.
178. Jacob E, Erickson-Johnson M, Wang X, et al. Assessment of MDM2 amplification using fluorescence in situ hybridization on
179. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
180. Lucas DR, Nascimento AG, Sanjay BK, Rock MG Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994, 102:677-683.
181. Oliveira AM, Dei Tos AP, Fletcher CD, Nascimento AG Primary giant cell tumor of soft tissues: A study of 22 cases. Am J Surg Pathol 2000, 24:248-256.
182. Pedeutour F, Suijkerbuijk RF, Forus A, et al. Complex composition and coamplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 1994, 10:85-94.
183. Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999, 24:30-41.
184. Sandberg AA Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Liposarcoma. Cancer Genet Cytogenet 2004, 155:1-24.
185. Weaver J, et al. Fluorescence in situ hybridization (FISH) for MDM2 gene amplification in formalin-fixed paraffin-embedded tissue (FFPET) as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2007, 20(21A-22A 78 Suppl 2).
186. Weiss SW, Goldblum JR Liposarcoma. Enzinger and Weiss's soft tissue tumors 2001, 641. Mosby, St Louis. S.W. Weiss, J.R. Goldblum (Eds.).
187. Weiss SW, Rao VK Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of "dedifferentiation.". Am J Surg Pathol 1992, 16:1051-1058.